Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Graybug Vision stock | $3.39

Learn how to easily invest in Graybug Vision stock.

Graybug Vision Inc is a biotechnology business based in the US. Graybug Vision shares (GRAY) are listed on the NASDAQ and all prices are listed in US Dollars. Graybug Vision employs 27 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Graybug Vision

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GRAY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Graybug Vision stock price (NASDAQ: GRAY)

Use our graph to track the performance of GRAY stocks over time.

Graybug Vision shares at a glance

Information last updated 2021-10-16.
Latest market close$3.39
52-week range$3.05 - $35.18
50-day moving average $3.67
200-day moving average $4.29
Wall St. target price$4.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.15

Buy Graybug Vision shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Graybug Vision stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Graybug Vision price performance over time

Historical closes compared with the close of $3.39 from 2021-10-21

1 week (2021-10-15) -4.24%
1 month (2021-09-22) -4.78%
3 months (2021-07-22) -23.30%
6 months (2021-04-22) -29.52%
1 year (2020-10-22) -76.64%
2 years (2019-10-18) N/A
3 years (2018-10-18) N/A
5 years (2016-10-18) N/A

Graybug Vision financials

Gross profit TTM $0
Return on assets TTM -41.85%
Return on equity TTM -70.36%
Profit margin 0%
Book value $3.70
Market capitalisation $75.3 million

TTM: trailing 12 months

Shorting Graybug Vision shares

There are currently 746,503 Graybug Vision shares held short by investors – that's known as Graybug Vision's "short interest". This figure is 2.3% up from 729,445 last month.

There are a few different ways that this level of interest in shorting Graybug Vision shares can be evaluated.

Graybug Vision's "short interest ratio" (SIR)

Graybug Vision's "short interest ratio" (SIR) is the quantity of Graybug Vision shares currently shorted divided by the average quantity of Graybug Vision shares traded daily (recently around 204521.36986301). Graybug Vision's SIR currently stands at 3.65. In other words for every 100,000 Graybug Vision shares traded daily on the market, roughly 3650 shares are currently held short.

To gain some more context, you can compare Graybug Vision's short interest ratio against those of similar companies.

However Graybug Vision's short interest can also be evaluated against the total number of Graybug Vision shares, or, against the total number of tradable Graybug Vision shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Graybug Vision's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Graybug Vision shares in existence, roughly 40 shares are currently held short) or 0.0931% of the tradable shares (for every 100,000 tradable Graybug Vision shares, roughly 93 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Graybug Vision.

Find out more about how you can short Graybug Vision stock.

Graybug Vision share dividends

We're not expecting Graybug Vision to pay a dividend over the next 12 months.

Graybug Vision overview

Graybug Vision, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc.

Frequently asked questions

What percentage of Graybug Vision is owned by insiders or institutions?
Currently 10.42% of Graybug Vision shares are held by insiders and 62.661% by institutions.
How many people work for Graybug Vision?
Latest data suggests 27 work at Graybug Vision.
When does the fiscal year end for Graybug Vision?
Graybug Vision's fiscal year ends in December.
Where is Graybug Vision based?
Graybug Vision's address is: 275 Shoreline Drive, Redwood City, CA, United States, 94065
What is Graybug Vision's ISIN number?
Graybug Vision's international securities identification number is: US38942Q1031

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site